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Impact of Diabetes Mellitus and Chronic Kidney Disease on
Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist
Effects in Patients With Acute Coronary Syndromes: Insights From
the PLATO Trial
Francesco Franchi, MD; Stefan K. James, MD, PhD; Tatevik Ghukasyan Lakic, MSc; Andrzej J. Budaj, MD, PhD; Jan H. Cornel, MD, PhD;
Hugo A. Katus, MD; Matyas Keltai, MD, DSc; Frederic Kontny, MD, PhD; Basil S. Lewis, MD; Robert F. Storey, MD, DM;
Anders Himmelmann, MD, PhD; Lars Wallentin, MD, PhD; Dominick J. Angiolillo, MD, PhD; on behalf of the PLATO Investigators*
Background-—There are limited data on how the combination of diabetes mellitus (DM) and chronic kidney disease (CKD) affects
cardiovascular outcomes as well as response to different P2Y12 receptor antagonists, which represented the aim of the present
investigation.
Methods and Results-—In this post hoc analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial, which randomized
acute coronary syndrome patients to ticagrelor versus clopidogrel, patients (n=15 108) with available DM and CKD status were
classiﬁed into 4 groups: DM+/CKD+ (n=1058), DM+/CKD (n=2748), DM/CKD+ (n=2160), and DM/CKD (n=9142). The
primary efﬁcacy end point was a composite of cardiovascular death, myocardial infarction, or stroke at 12 months. The primary
safety end point was PLATO major bleeding. DM+/CKD+ patients had a higher incidence of the primary end point compared with
DM/CKD patients (23.3% versus 7.1%; adjusted hazard ratio 2.22; 95% CI 1.88–2.63; P<0.001). Patients with DM+/CKD and
DM/CKD+ had an intermediate risk proﬁle. The same trend was shown for the individual components of the primary end point
and for major bleeding. Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across
subgroups (P-interaction=0.264), but with an increased absolute risk reduction in DM+/CKD+. The effects on major bleeding were
also consistent across subgroups (P-interaction=0.288).
Conclusions-—In acute coronary syndrome patients, a gradient of risk was observed according to the presence or absence of DM
and CKD, with patients having both risk factors at the highest risk. Although the ischemic beneﬁt of ticagrelor over clopidogrel was
consistent in all subgroups, the absolute risk reduction was greatest in patients with both DM and CKD.
Clinical Trial Registration-—URL: http://www.clinicatrials.gov. Unique identiﬁer: NCT00391872. ( J Am Heart Assoc. 2019;8:
e011139. DOI: 10.1161/JAHA.118.011139.)
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P
atients with diabetes mellitus (DM) are at increased risk
of atherothrombotic events.
1
Importantly, DM is a key
risk factor for the development of chronic kidney disease
(CKD), a well-known cardiovascular risk factor.
2,3
These
observations underscore the importance of antiplatelet
therapy for secondary prevention of atherothrombotic
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recurrences in these high-risk patients. Dual antiplatelet
therapy with aspirin and a P2Y12 receptor inhibitor is the
standard of care for secondary prevention in acute coronary
syndrome (ACS) patients.
4
Guidelines recommend that the
more potent P2Y12 receptor inhibitors (ie, prasugrel or
ticagrelor) be preferred over clopidogrel for the treatment of
ACS patients because of their greater beneﬁt in reducing the
risk of cardiovascular events in these patients, albeit at the
expense of increased bleeding.
4,5
Nevertheless, clopidogrel
remains widely used in ACS patients.
6,7
DM patients treated
with clopidogrel have increased rates of recurrent
atherothrombotic events, which may be in part because of
reduced platelet inhibitory effects of clopidogrel consistently
observed among these subjects.
1,8–11
Although studies
assessing the impact of CKD status on clopidogrel-induced
antiplatelet effects have yielded conﬂicting ﬁndings, pharma-
codynamic assessments conducted among DM patients have
shown a greater magnitude of impaired clopidogrel-induced
platelet inhibition among those with CKD compared with
those without CKD.
12–19
These observations, as well as those from other small
observational studies, suggest that the concomitant presence
of DM and CKD status can increase ischemic event rates,
underscoring the need for more effective platelet-inhibiting
therapies in these high-risk patients.
20,21
However, to date
most large-scale studies assessing how the presence of DM
and CKD affects cardiovascular outcomes and the relative
impact of speciﬁc antiplatelet treatment regimens, in partic-
ular P2Y12 receptor inhibitors, have considered these risk
factors separately.
1,2
Indeed, the ever-growing prevalence of
CKD in patients with DM underscores the need to better risk
stratify these patient cohorts. The aim of this analysis was to
assess clinical outcomes in ACS patients from the PLATO
(Platelet Inhibition and Patient Outcomes) trial according to
the presence or absence of DM and CKD, as well as the
differential effects of P2Y12-inhibiting therapies (ticagrelor
versus clopidogrel) in these populations.
Methods
The PLATO trial (www.ClinicalTrials.gov NCT00391872) was
conducted from October 2006 to February 2009 and
randomly assigned 18 624 patients with ST-segment–eleva-
tion myocardial infarction (MI), non-ST–segment elevation MI,
or unstable angina, treated with an invasive or a noninvasive
approach, to receive either ticagrelor or clopidogrel as soon
as possible after admission. Details of study design, patients,
outcome deﬁnitions, and results have been described else-
where.
22
In brief, ticagrelor was administered as a 180-mg
loading dose followed by 90 mg twice daily. Patients assigned
to clopidogrel received a maintenance dose of 75 mg daily.
Those who were clopidogrel na€ıve were also administered a
300- to 600-mg loading dose. All patients received aspirin
unless intolerant. The randomized treatment continued for a
minimum of 6 to a maximum of 12 months (median duration
9.1 months). The primary efﬁcacy end point was a composite
of cardiovascular death, MI, or stroke. The primary safety end
point was all major bleeding according to PLATO deﬁnition.
Bleeding events were also deﬁned according to the Throm-
bolysis In Myocardial Infarction (TIMI) and Global Use of
Strategies to Open Occluded Arteries (GUSTO) classiﬁca-
tions.
22
Patients randomized in PLATO with available DM and CKD
status at the time of randomization were included in the
present analysis. Accordingly, patients were classiﬁed into 4
groups: DM+/CKD+, DM+/CKD, DM/CKD+, and DM/
CKD. DM status was deﬁned by the investigators at the time
of randomization. Serum glucose and hemoglobin A1c were
also measured and used to further characterize the study
population, with poor glycemic control deﬁned as levels above
the median of serum glucose (6.8 mmol/L) and the median of
percentage hemoglobin A1c (6.0%).
23
CKD was deﬁned as a
creatinine clearance (CrCl) <60 mL/min according to the
Cockcroft-Gault equation.
24
There were no exclusion criteria
for renal dysfunction in the PLATO trial except for the
requirement of dialysis. In an exploratory analysis, CKD status
was also stratiﬁed according to the Modiﬁcation of Diet in
Renal Disease and Chronic Kidney Disease Epidemiology
Clinical Perspective
What Is New?
• Acute coronary syndrome patients with diabetes mellitus
and chronic kidney disease are at markedly increased risk
for long-term atherothrombotic events compared with
patients without these risk factors, as well as with those
with only 1 of these.
• Although the ischemic beneﬁt of ticagrelor versus clopido-
grel was consistent in all patient subgroups, the magnitude
of beneﬁt was enhanced according to the patient risk
proﬁle.
What Are the Clinical Implications?
• There is a need to deﬁne the most effective treatment
options for these high-risk patients, including strategies to
reduce the risk of developing chronic kidney disease in
patients with diabetes mellitus.
• Similarly, in patients with established chronic kidney
disease, glucose control is also critical to reduce the risk
of developing diabetes mellitus.
• Clinicians should use more potent platelet-inhibiting therapy
in acute coronary syndrome patients with diabetes mellitus
and chronic kidney disease who are often undertreated
because of high perceived risk of bleeding.
DOI: 10.1161/JAHA.118.011139 Journal of the American Heart Association 2
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Collaboration equations.
25
In addition, in a subgroup of
patients (n=13 688), kidney function was assessed based on
cystatin C levels measured on stored samples using the
Creatinine-Cystatin C Chronic Kidney Disease Epidemiology
Collaboration equation.
26
The PLATO trial adhered to the Declaration of Helsinki and
was approved by the appropriate ethical review boards. All
patients provided written informed consent. The data, analytic
methods, and study materials will not be made available to
other researchers for purposes of reproducing the results or
replicating the procedure.
Statistical Analysis
Categorical baseline variables are presented as frequencies
and percentages and compared by DM/CKD group using v2
tests. Continuous baseline variables are presented as medi-
ans and 25th to 75th percentiles and compared by DM/CKD
group using Kruskal–Wallis tests. Kaplan–Meier estimated
event rates from randomization to 12 months were plotted by
DM/CKD groups. Cox proportional hazards models were used
to assess the associations between CKD-DM status and
clinical end points. Multivariable Cox regression models
included randomized treatment, age, sex, body mass index,
heart rate, prior MI, hypertension, dyslipidemia, smoking
status, previous percutaneous coronary intervention or coro-
nary artery bypass graft (CABG), and type of ACS as
covariates. The interaction between DM/CKD status and
randomized treatment was examined by adding an interaction
term to the model. Results are presented as adjusted hazard
ratios (HR) with 95% CI. In the comparisons between DM/
CKD groups, HRs are reported using DM/CKD group as
reference. All statistical analyses were performed with SAS
9.4 (SAS Institute, Cary, NC). A 2-sided P value of <0.05 was
considered statistically signiﬁcant for differences between
groups and treatments.
Results
Patients and Outcomes According to CKD and DM
Status
Among patients randomized in the PLATO trial, 15 108 had
DM and CKD status available and were classiﬁed as follows:
DM+/CKD+ (n=1058), DM+/CKD (n=2748), DM/CKD+
(n=2160), and DM/CKD (n=9142). Baseline characteris-
tics are reported in Table 1. After excluding patients who
prematurely discontinued because of death, the number of
patients who discontinued treatment during follow-up was low
(43 in the CKD+DM+ group [0.28%], 71 in the CKDDM+
group [0.47%], 83 in the CKD+DM group [0.55%], and 206 in
the CKDDM group [1.36%]). Patients with DM+/CKD+
more frequently had a prior history of cardiovascular disease,
including MI, stroke, and peripheral arterial disease; were
more frequently diagnosed with non-ST-elevation ACS rather
than ST-elevation MI; and were more frequently treated with a
noninvasive approach.
Patients with DM+/CKD+ had an over 3-fold higher
incidence of the primary end point at 12 months compared
with DM/CKD patients (23.3% versus 7.1%; adjusted HR
2.22; 95% CI 1.88–2.63). Patients with DM+/CKD (10.7%;
adjusted HR 1.34; 95% CI 1.16–1.55) and DM/CKD+
(15.8%; adjusted HR 1.60; 95% CI 1.37–1.86) had an
intermediate risk proﬁle (P for trend <0.001; Figure 1). The
same trend was shown for the individual components of the
primary end point, cardiovascular death, MI, and stroke, as
well as for all-cause mortality (Figure 2). Patients with DM+/
CKD+ also had the highest risk of PLATO-deﬁned major
bleeding compared with DM/CKD patients (14.8% versus
8.5%; adjusted HR 1.47; 95% CI 1.21–1.77) and patients with
DM+/CKD (11.7%; adjusted HR 1.34; 95%; CI: 1.17–1.54)
or DM/CKD+ (11.8%; adjusted HR 1.13; 95% CI 0.96–1.33)
(Figure 3A). Non-CABG-related major bleeding rates were
higher in patients with DM+/CKD+ and DM/CKD+ com-
pared with patients with DM+/CKD and DM/CKD
(Figure 3B). Major bleeding deﬁned according to TIMI and
GUSTO criteria showed a similar trend (Figure 4). Results
were consistent when measures of poor glycemic control and
alternative deﬁnitions of CKD were considered (Table 2).
Outcomes of Ticagrelor Versus Clopidogrel
According to CKD and DM Status
Compared with clopidogrel, ticagrelor signiﬁcantly reduced
the incidence of the primary end point consistently across
subgroups (P interaction=0.3). However, the absolute risk
reduction (ARR) with ticagrelor versus clopidogrel was con-
siderably higher in DM+/CKD+ patients (11.26%; adjusted HR
0.78; 95% CI 0.61–1.01) compared with DM/CKD (1.37%;
adjusted HR 0.86; 95% CI 0.73–1.00) (Figures 5 and 6).
Consistent ﬁndings were shown on all the components of the
primary end point (Table 3). In particular, ticagrelor led to a
5.8% ARR in cardiovascular death in patients with DM+/CKD+
compared with a 0.2% reduction in DM/CKD patients.
Accordingly, the number-needed-to-treat for the primary end
point was 8.9 in DM+/CKD+ and 73 in DM/CKD, and for
cardiovascular death 17.2 in DM+/CKD+ and 500 in DM/
CKD.
The effects of ticagrelor versus clopidogrel on PLATO-
deﬁned major bleeding were consistent across subgroups
(P interaction=0.3). In particular, there was no increased risk
of major bleeding with ticagrelor compared with clopidogrel in
the subgroup of patients with DM+/CKD+ (27.4% versus
26.9%; HR 1.02; 95% CI 0.75–1.40). Accordingly, the effects
DOI: 10.1161/JAHA.118.011139 Journal of the American Heart Association 3
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Table 1. Baseline Characteristics by DM/CKD Status
Group of Characteristics Characteristic (at Baseline) DM+/CKD+ (n=1058) DM+/CKD (n=2748) DM/CKD+ (n=2160) DM/CKD (n=9142) P Value
Demographics Age (y), median (Q1–Q3) 72 (66–78) 61 (55–68) 74 (68–79) 59 (52–66) <0.0001
Age ≥75 y 429 (40.5%) 233 (8.5%) 1060 (49.1%) 604 (6.6%) <0.0001
Female sex 456 (43.1%) 851 (31.0%) 823 (38.1%) 2176 (23.8%) <0.0001
Weight (kg), median (Q1–Q3) 75 (65–84) 84 (74–95) 72 (62–80) 80 (70–90) <0.0001
Weight <60 kg 107 (10.1%) 120 (4.4%) 349 (16.2%) 498 (5.4%) <0.0001
Height (cm), median (Q1–Q3) 165 (160–172) 170 (163–175) 167 (160–173) 171 (165–177) <0.0001
BMI (kg/m2), median (Q1–Q3) 26.9 (24.6–30.2) 29.3 (26.4–32.9) 25.4 (23.2–28.1) 27.4 (24.8–30.2) <0.0001
Waist circumference (cm), median (Q1–Q3) 99 (91–108) 103 (94–112) 95 (86–102) 97 (90–105) <0.0001
Race, n (%) White 922 (87.1) 2515 (91.5) 1928 (89.3) 8553 (93.6) <0.0001
Black 22 (2.1) 46 (1.7) 28 (1.3) 71 (0.8)
Asian 84 (7.9) 160 (5.8) 160 (7.4) 457 (5.0)
Other 30 (2.8) 27 (1.0) 44 (2.0) 61 (0.7)
Cardiovascular risk factors, n (%) Habitual smoker 130 (12.3) 800 (29.1) 413 (19.1) 4061 (44.4) <0.0001
Hypertension 925 (87.4) 2162 (78.7) 1574 (72.9) 5187 (56.7) <0.0001
Dyslipidemia 622 (58.8) 1629 (59.3) 916 (42.4) 3816 (41.7) <0.0001
History, n (%) Angina pectoris 651 (61.5) 1423 (51.8) 1137 (52.6) 3647 (39.9) <0.0001
Myocardial infarction 360 (34.0) 676 (24.6) 556 (25.7) 1507 (16.5) <0.0001
Congestive heart failure 176 (16.6) 188 (6.8) 229 (10.6) 255 (2.8) <0.0001
PCI 217 (20.5) 462 (16.8) 290 (13.4) 1025 (11.2) <0.0001
CABG 139 (13.1) 236 (8.6) 155 (7.2) 350 (3.8) <0.0001
TIA 48 (4.5) 75 (2.7) 81 (3.8) 191 (2.1) <0.0001
Nonhemorrhagic stroke 96 (9.1) 129 (4.7) 117 (5.4) 242 (2.6) <0.0001
Peripheral arterial disease 149 (14.1) 210 (7.6) 163 (7.5) 422 (4.6) <0.0001
Medications on arrival, n (%) Aspirin 1007 (95.2) 2618 (95.3) 2033 (94.1) 8756 (95.8) 0.01
b-Blockade 842 (79.6) 2257 (82.1) 1613 (74.7) 6739 (73.7) <0.0001
ACE-inhibition and/or ARB 806 (76.2) 2049 (74.6) 1397 (64.7) 5361 (58.6) <0.0001
Statin 823 (77.8) 2230 (81.1) 1651 (76.4) 7350 (80.4) <0.0001
Ca-inhibitor 276 (26.1) 539 (19.6) 352 (16.3) 1054 (11.5) <0.0001
Diuretic 497 (47.0) 793 (28.9) 758 (35.1) 1449 (15.8) <0.0001
Insulin treatment before admission 282 (26.7) 572 (20.8) 0.0001
Medications index event
to discharge, n (%)
GP 2b/3a inhibitor 177 (16.7) 734 (26.7) 413 (19.1) 2686 (29.4) <0.0001
Unfractionated heparin 524 (49.5) 1591 (57.9) 1195 (55.3) 5473 (59.9) <0.0001
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Table 1. Continued
Group of Characteristics Characteristic (at Baseline) DM+/CKD+ (n=1058) DM+/CKD (n=2748) DM/CKD+ (n=2160) DM/CKD (n=9142) P Value
Low-molecular-weight heparin 590 (55.8) 1460 (53.1) 1199 (55.5) 4734 (51.8) 0.003
Fondaparinux 34 (3.2) 74 (2.7) 74 (3.4) 249 (2.7) 0.3
Bivalirudin 25 (2.4) 90 (3.3) 34 (1.6) 158 (1.7) <0.0001
Intended approach Invasive 603 (57.0%) 1912 (69.6%) 1311 (60.7%) 6915 (75.6%) <0.0001
Noninvasive 455 (43.0%) 836 (30.4%) 849 (39.3%) 2227 (24.4%)
Final ACS diagnosis ST-elevation MI 244 (23.1%) 863 (31.4%) 638 (29.6%) 3980 (43.6%) <0.0001
Non-ST-elevation MI 559 (52.9%) 1259 (45.8%) 1038 (48.2%) 3622 (39.6%)
Unstable angina 224 (21.2%) 566 (20.6%) 427 (19.8%) 1336 (14.6%)
Other 29 (2.7%) 60 (2.2%) 50 (2.3%) 199 (2.2%)
Randomized treatment Delay from start of pain (h), median (Q1–Q3) 14.2 (6.8–21.2) 12.7 (5.7–20.4) 14.0 (5.8–21.1) 10.2 (4.3–19.0) <0.0001
Treatment duration (d), median (Q1–Q3) 258 (55–361) 276 (179–365) 265 (73–363) 284 (184–366) <0.0001
Biomarkers Creatinine (lmol/L), median (Q1–Q3) 115.0 (106.0–141.0) 80.0 (70.7–88.0) 106.0 (97.0–124.0) 80.0 (71.0–88.0) <0.0001
Glucose (mmol/L), median (Q1–Q3) 9.9 (7.2–13.5) 9.7 (7.2–13.2) 6.5 (5.6–7.9) 6.4 (5.6–7.7) <0.0001
HbA1c (mmol/mol), median (Q1–Q3) 7.5 (6.6–8.7) 7.6 (6.7–9.1) 5.9 (5.6–6.2) 5.8 (5.6–6.1) <0.0001
Hemoglobin (mmol/mol), median (Q1–Q3) 128.0 (116.0–140.0) 139.0 (128.0–149.0) 134.0 (123.0–145.0) 142.0 (132.0–151.0) <0.0001
NT-proBNP (pmol/L), median (Q1–Q3) 1734 (610.0–4071) 395.0 (146.0–953.0) 1002 (320.0–2544) 277.0 (99.0–721.0) <0.0001
Troponin I lg/L, median (Q1–Q3) 1.10 (0.12–6.00) 0.95 (0.11–4.30) 1.00 (0.11–5.70) 0.90 (0.12–4.70) 0.01
Creatinine (mg/dL), median (Q1–Q3) 1.3 (1.2–1.6) 0.9 (0.8–1.0) 1.2 (1.1–1.4) 0.9 (0.8–1.0) <0.0001
CrCl (mL/min), median (Q1–Q3) 48.4 (38.9–55.1) 86.7 (73.2–104.5) 50.3 (42.7–55.9) 87.7 (74.5–104.0) <0.0001
ACE indicates angiotensin converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; CKD, chronic kidney disease; CrCl, creatinine clearance by
Cockcroft-Gault equation; DM, diabetes mellitus; GP, glycoprotein; HbA1c, hemoglobin A1c; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; TIA, transient ischemic
attack.
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on non-CABG-related major bleeding were also consistent
regardless of CKD/DM status, although the increase in
bleeding risk with ticagrelor was numerically higher in patients
with CKD (both DM+/CKD+ and DM/CKD+) (Table 3). The
number-needed-to-harm for all major bleeding was 208 in
DM+/CKD+ and 49 in DM/CKD and for non-CABG-related
major bleeding was 73 in DM+/CKD+ and 105 in DM/
CKD. Major bleeding deﬁned according to TIMI and GUSTO
criteria followed the same trend (Table 4).
Results were consistent when measures of poor glycemic
control and alternative deﬁnitions of CKD were considered. In
particular, with poor glycemic control deﬁned by hemoglobin
A1c and CKD deﬁned by the Creatinine-Cystatin C Chronic
Kidney Disease Epidemiology Collaboration equation, the
effects of ticagrelor versus clopidogrel on ischemic and
bleeding events were consistent across subgroups (Table 5).
In patients with DM+/CKD+, ticagrelor led to a 14% ARR in
the primary end point and a 9% ARR in cardiovascular death
compared with clopidogrel with no signiﬁcant increase in
major bleeding.
Discussion
The data from the present post hoc analysis of the PLATO trial
represent the largest exploring the impact of having DM, CKD,
or both, on clinical outcomes in ACS patients. Our study
showed that (1) the concomitant presence of CKD and DM is
not uncommon in patients with ACS, representing 7% of the
overall study population; (2) patients with CKD and DM are
more likely to already have established atherosclerotic disease,
more frequently present with a non-ST-elevation ACS and are
more likely to be treated with a noninvasive approach; (3)
patients with either DMor CKD are at increased risk of ischemic
events compared with patients without these risk factors; and
the combination of DM and CKD status is associated with an
over 3-fold increased risk of ischemic events compared with
patients without these risk factors, including a 6-fold increase
in cardiovascular death; (4) the presence of DM and CKD is
associated with a signiﬁcant increase in major bleeding and
non-CABG-related major bleeding, but not in CABG-related
bleeding; (5) the beneﬁt of ticagrelor over clopidogrel on
ischemic outcomes is consistent across DM and CKD status,
but themagnitude of absolute beneﬁt is enhanced in higher-risk
patients; in particular, in patients with DM and CKD ticagrelor
led to a 22% relative risk reduction and an 11% ARR in the
primary end point compared with clopidogrel, including a 21%
relative risk reduction and an 5.8% ARR in cardiovascular death;
and (6) there was no signal of increased risk of bleeding with
ticagrelor in patients with CKD and DM as compared with the
other subgroups.
Figure 1. Kaplan–Meier event rate curves for the cumulative incidence of the primary composite end point of
cardiovascular (CV) death, myocardial infarction (MI), and stroke stratiﬁed by DM/CKD status. P value represents
theoverall comparisonamonggroupsaccording toDM/CKDstatus. Themodel is adjusted for age, sex, bodymass
index, heart rate, prior myocardial infarction, hypertension, dyslipidemia, angina pectoris, smoking status,
previous percutaneous coronary intervention or coronary artery bypass graft, type of acute coronary syndrome
and randomized treatment. CKD indicates chronic kidney disease; DM, diabetes mellitus.
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DM and CKD have both been independently associated with
an increased risk of cardiovascular events, which may be
attributed to abnormalities speciﬁc to these patients favoring a
prothrombotic and pro-inﬂammatory status.
1,2
Among patients
with DM, impaired clopidogrel-induced antiplatelet effects
leading to high levels of platelet reactivity has been largely
attributed to an attenuation of clopidogrel’s pharmacokinetic
proﬁle, characterized by lower active metabolite levels, and in
part to dysregulation of the P2Y12 receptor signaling path-
way.
9,10,27
Subgroup analysis ofmajor clinical trials have shown
a reduced beneﬁt of clopidogrel in CKD patients.
2
Patients with
CKD are characterized by upregulation of the P2Y12 signaling
pathway induced by dinucleoside polyphosphates and impaired
hepatic function, which can potentially impact clopidogrel
metabolism.
28–32
However, while pharmacodynamic studies
have consistently shown DM to be associated with impaired
clopidogrel-induced antiplatelet effects, results have been
conﬂicting when assessing how CKD affects clopidogrel
response. These observations may be attributed to con-
founders within the heterogeneous study populations in which
these studies have been performed.
12–19
Pharmacodynamic
assessments speciﬁcally conducted among DM patients who
also have CKD have shown these patients to have greater
impairment of clopidogrel-induced platelet inhibition compared
with those without CKD.
13,15,16
However, in the absence of DM,
renal function has not always been shown to affect clopido-
grel’s antiplatelet effects.
12,13,17–19
Overall, these ﬁndings
suggest that there may be some level of synergism of DM and
CKD on platelet reactivity in clopidogrel-treated patients, which
would be in line with the clinical observations of the present
investigation.
16
A post hoc analysis of the FREEDOM (Comparison of Two
Treatments for Multivessel Coronary Artery Disease in
Individuals With Diabetes) trial assessing revascularization
strategies (surgical versus percutaneous) among DM
patients (n=1843) with multivessel coronary artery disease
Figure 2. Kaplan–Meier event rate curves for the cumulative incidence of (A) cardiovascular (CV) death, (B) myocardial infarction (MI), (C)
stroke, and (D) all-cause mortality stratiﬁed by DM/CKD status. P value represents the overall comparison among groups according to DM/CKD
status. The model is adjusted for age, sex, body mass index, heart rate, prior myocardial infarction, hypertension, dyslipidemia, angina pectoris,
smoking status, previous percutaneous coronary intervention or coronary artery bypass graft, type of acute coronary syndrome, and randomized
treatment. CKD indicates chronic kidney disease; DM, diabetes mellitus.
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evaluated the impact of CKD status on clinical outcomes.
20
In this analysis, CKD affected clinical outcomes irrespective
of the strategy used for revascularization, leading to a
nearly 2-fold risk increase in all-cause mortality, cardiovas-
cular death, and stroke and a 1.5-fold risk increase in major
bleeding.
20
Our analysis represents the largest data set to
Figure 3. Kaplan–Meier event rate curves for the cumulative incidence of (A) major bleeding, and (B) non-
CABG-related major bleeding stratiﬁed by DM/CKD status. P value represents the overall comparison
among groups according to DM/CKD status. Bleeding is deﬁned according to PLATO criteria. The model is
adjusted for age, sex, body mass index, heart rate, prior myocardial infarction, hypertension, dyslipidemia,
angina pectoris, smoking status, previous percutaneous coronary intervention, or coronary artery bypass
graft, type of acute coronary syndrome, and randomized treatment. CABG indicates coronary artery bypass
graft; CKD, chronic kidney disease; DM, diabetes mellitus; PLATO, Platelet Inhibition and Patient Outcomes.
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unravel the contributing role of DM and CKD on cardiovas-
cular outcomes. We extend the ﬁndings from the FREEDOM
analysis to ACS patients receiving dual antiplatelet therapy
undergoing different treatment strategies (invasive or non-
invasive), showing that the presence of either DM or CKD
increases long-term cardiovascular events to a similar
Figure 4. Kaplan–Meier event rate curves for the cumulative incidence of major/severe bleeding
according to (A) TIMI, and (B) GUSTO criteria stratiﬁed by DM/CKD status. P value represents the overall
comparison among groups according to DM/CKD status. The model is adjusted for age, sex, body mass
index, heart rate, prior myocardial infarction, hypertension, dyslipidemia, angina pectoris, smoking status,
previous percutaneous coronary intervention or coronary artery bypass graft, type of acute coronary
syndrome, and randomized treatment. CKD indicates chronic kidney disease; DM, diabetes mellitus;
GUSTO, Global Use of Strategies to Open Occluded Arteries; TIMI, thrombolysis in myocardial infarction.
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Table 2. Ischemic and Bleeding Outcomes According to DM/CKD Subgroup, With Poor Glycemic Control Deﬁned by HbA1c and
CKD Deﬁned by the Creatinine-Cystatin C CKD-EPI Equation
DM/CKD Subgroup No. of Events No. of Patients Event Rate (%)* HR (95% CI)† P Value‡
Cardiovascular death/MI/stroke
DM/CKD 392 1264 6.9 <0.0001
DM+/CKD 580 5726 10.1 1.33 (1.16–1.52)
DM/CKD+ 123 734 16.8 1.72 (1.39–2.13)
DM+/CKD+ 263 1264 20.8 2.09 (1.76–2.49)
Cardiovascular death
DM/CKD 121 5673 2.1 <0.0001
DM+/CKD 215 5726 3.8 1.54 (1.23–1.94)
DM/CKD+ 65 734 8.9 2.50 (1.81–3.44)
DM+/CKD+ 155 1264 12.3 3.44 (2.64–4.48)
MI
DM/CKD 258 5673 4.5 <0.0001
DM+/CKD 357 5726 6.2 1.24 (1.05–1.47)
DM/CKD+ 69 734 9.4 1.60 (1.21–2.12)
DM+/CKD+ 130 1264 10.3 1.66 (1.32–2.10)
All-cause death
DM/CKD 145 5673 2.6 <0.0001
DM+/CKD 238 5726 4.2 1.45 (1.17–1.79)
DM/CKD+ 72 734 9.8 2.21 (1.63–2.99)
DM+/CKD+ 174 1264 13.8 3.19 (2.49–4.08)
Stroke
DM/CKD 46 5673 0.8 0.1679
DM+/CKD 74 5726 1.3 1.43 (0.98–2.08)
DM/CKD+ 11 734 1.5 1.15 (0.58–2.29)
DM+/CKD+ 27 1264 2.1 1.67 (0.99–2.81)
Major bleeding
DM/CKD 484 5673 8.5 0.0039
DM+/CKD 629 5726 11.0 1.26 (1.11–1.42)
DM/CKD+ 86 734 11.7 1.14 (0.90–1.45)
DM+/CKD+ 148 1264 11.7 1.14 (0.94–1.39)
Non-CABG-related major bleeding
DM/CKD 161 5673 2.8 0.0070
DM+/CKD 180 5726 3.1 1.00 (0.81–1.25)
DM/CKD+ 44 734 6.0 1.34 (0.94–1.91)
DM+/CKD+ 88 1264 7.0 1.55 (1.16–2.07)
CABG-related major bleeding
DM/CKD 367 5628 6.5 0.1678
DM+/CKD 366 5673 6.5 1.02 (0.88–1.18)
DM/CKD+ 44 727 6.1 0.96 (0.69–1.32)
DM+/CKD+ 96 1250 7.7 1.29 (1.01–1.65)
The model is adjusted for age, sex, BMI, heart rate, prior myocardial infarction, hypertension, dyslipidemia, angina pectoris, smoking status, previous PCI or CABG, type of ACS deﬁne and
randomized treatment. BMI indicates body mass index; CABG, coronary artery bypass graft; CKD, chronic kidney disease; CKD-EPI, chronic kidney disease epidemiology collaboration; DM,
diabetes mellitus; HbA1c, hemoglobin A1c; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention.
*The crude event rate, (no. events/no. of subjects)9100%.
†
Subgroup DM/CKD is the reference category.
‡P value for the effect of DM/CKD subgroup.
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extent but when these risk factors are combined, this risk
is further ampliﬁed. Notably, this was consistent using
multiple deﬁnitions of DM and CKD, supporting the validity
of our study ﬁndings. The ever-rising prevalence of both DM
and CKD underscore the relevance of these observations. In
fact, both clinical disorders are pandemic public health
problems. CKD has a prevalence of 13% in the United
States and up to 17% in Europe.
3,33
Importantly, DM is a
key risk factor for the development of CKD, and about one
third of DM patients are found to have CKD.
3
Therefore,
with the increasing prevalence of DM, which is expected to
double over the next 20 years, the prevalence of CKD is
also expected to rise.
34
These observations underscore the
need for deﬁning the most effective treatment options for
these high-risk patients, including strategies to reduce the
risk of developing CKD in patients with DM. To this extent,
sodium-glucose cotransporter-2 inhibitors are new antihy-
perglycemic therapies known to reduce long-term decline in
kidney function.
35,36
Similarly, in patients with established
CKD, glucose control is also critical to reduce the risk of
developing DM.
Ticagrelor is characterized by more potent and predict-
able antiplatelet effects compared with clopidogrel, which
translate into better clinical outcomes in ACS patients, albeit
at the expense of an increased risk of major bleeding.
22,37
Pharmacodynamic assessments have shown that the
enhanced potency of ticagrelor over clopidogrel persists in
patients with DM,
38,39
and in the DM subgroup of PLATO,
compared with clopidogrel, ticagrelor was associated with a
2.1% ARR in the primary end point, a ﬁnding that was
consistent with the overall trial results (P-interaction: 0.49).
23
In patients with CKD, ticagrelor led to a 4.7% ARR of the
primary ischemic end point, which was also consistent with
the overall trial results (P-interaction: 0.13).
24
However, there
are limited data on the pharmacodynamic effects of ticagrelor
in CKD patients.
40,41
The present study ﬁndings show that,
although the beneﬁt of ticagrelor over clopidogrel is consis-
tent across subgroups (P-interaction: 0.264), the enhanced
beneﬁt of ticagrelor in patients with CKD is even greater in
patients who also have DM (11% ARR), including a 5.8% ARR in
cardiovascular mortality. Indeed, the higher event rates that
characterize these patients can contribute to the greater
magnitude of the treatment effect associated with more
potent platelet P2Y12 inhibition induced by ticagrelor. In
addition, prior investigations supporting impaired clopidogrel-
induced platelet inhibition in DM patients, in particular those
Figure 5. Hazard ratios (HR) with 95% CI for the primary composite end point (cardiovascular death,
myocardial infarction, and stroke) of ticagrelor (T) vs clopidogrel (C) stratiﬁed by DM/CKD status. The
model is adjusted for age, sex, body mass index, heart rate, prior myocardial infarction, hypertension,
dyslipidemia, angina pectoris, smoking status, previous percutaneous coronary intervention or coronary
artery bypass graft, type of acute coronary syndrome, and randomized treatment. CKD indicates chronic
kidney disease; DM, diabetes mellitus.
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also with CKD, may contribute to these ﬁndings.
9–12,14,16,17
However, because DM and CKD patients are characterized by
enhanced vascular inﬂammation and endothelial dysfunction,
it cannot be excluded that they could be more susceptible to
the off-target effects of ticagrelor. In fact, ticagrelor increases
adenosine levels by inhibiting its reuptake by erythrocytes and
adenosine may modulate inﬂammatory response and favor
vasodilation.
42
Patients with CKD and DM are overall at increased risk of
bleeding. This may explain why in some studies these patients
are less commonly treated with more potent platelet-
inhibiting therapies.
43,44
The increased risk for bleeding
among DM and CKD patients was also conﬁrmed in this
analysis. However, there was no increased risk of major
bleeding with ticagrelor versus clopidogrel in the subgroup of
patients with DM+/CKD+. The increase in non-CABG-related
major bleeding events was numerically higher in patients with
DM+/CKD+, but the relative risk was similar and the effect
was overall consistent across groups, also using different
bleeding deﬁnitions. These ﬁndings were also consistent
using multiple deﬁnitions of DM and CKD.
Study Limitations
The results of the present study should be interpreted in light
of some limitations. Patients with end-stage renal disease
requiring hemodialysis were excluded from the trial; therefore,
our results are not applicable to this setting. Although we
used different deﬁnitions to deﬁne CKD status, we did not
measure albumin–creatinine ratio and therefore may have
underestimated the true prevalence of CKD. Accordingly, the
number of patients with CKD+ in our study population was
relatively small. CKD was deﬁned according to baseline
creatinine levels at the time of ACS presentation. Therefore,
creatinine clearance may not be reﬂective of steady-state
kidney function. Indeed, it may be argued that the results of
our study pertain to a cohort of CKD patients with mostly
moderate (stage 3) degree of renal impairment and the results
cannot be extrapolated to those with more advanced stages
of renal disease. Moreover, the present investigation does not
provide any mechanistic insights for the enhanced rates of
adverse outcomes and the inconsistent response to different
classes of P2Y12 inhibiting therapies among patients with
concomitant DM and CKD, which is a topic of ongoing
investigation (NCT02539160). It may be argued that there are
large baseline differences between the DM/CKD groups that
might not be possible to fully account for by covariate
adjustment. Although an age/sex/comorbid matched analy-
sis could have represented an option, this typically leads to
loss of information when not all subjects can be matched, and
a similar analysis would have resulted in smaller patient
cohorts and ultimately not reﬂective of risk proﬁle of this
patient population in real-world clinical practice. Finally, our
results derive from a post hoc subgroup analysis and should
Figure 6. Kaplan–Meier event rate curves for the cumulative incidence of the primary composite end
point of cardiovascular (CV) death, myocardial infarction, and stroke stratiﬁed by treatment group and DM/
CKD status. C indicates clopidogrel; CKD, chronic kidney disease; DM, diabetes mellitus; T, ticagrelor.
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as such be considered as hypothesis-generating and requiring
conﬁrmation in prospectively designed studies.
Conclusions
In conclusion, the results of the present analysis showed that
ACS patients with DM and CKD are at markedly increased risk
for long-term atherothrombotic events compared with patients
without these risk factors, as well as with those with only 1 of
these. Although the ischemic beneﬁt of ticagrelor versus
clopidogrel was consistent in all patient subgroups, the
magnitude of beneﬁt was enhanced according to the patient
risk proﬁle. Although patients with DM and CKD are at
increased risk of bleeding, there were no signals of increased
risk ofmajor bleeding events with ticagrelor. Overall, these data
underscore the need for using more potent platelet-inhibiting
therapy in ACS patients with DM and CKD who are often
undertreated because of high perceived risk of bleeding.
Table 3. Outcomes of Ticagrelor Versus Clopidogrel According to DM/CKD Status
DM/CKD Subgroup
Ticagrelor
Patients (N)
Clopidogrel
Patients (N)
Ticagrelor Event
Rate, N (%)
Clopidogrel Event
Rate, N (%) HR (95% CI)
P Value
Interaction
Cardiovascular death 0.3
DM+/CKD+ 521 537 55 (13.60) 77 (19.40) 0.79 (0.55–1.11)
DM/CKD+ 1043 1117 69 (8.33) 111 (12.80) 0.68 (0.51–0.92)
DM+/CKD 1363 1385 59 (5.30) 62 (5.38) 1.00 (0.70–1.44)
DM/CKD 4621 4521 98 (2.51) 104 (2.71) 0.93 (0.70–1.22)
MI 0.2
DM+/CKD+ 521 537 52 (13.79) 72 (19.66) 0.76 (0.53–1.09)
DM/CKD+ 1043 1117 77 (9.77) 100 (12.29) 0.83 (0.62–1.12)
DM+/CKD 1363 1385 93 (8.76) 84 (7.58) 1.13 (0.84–1.52)
DM/CKD 4621 4521 195 (5.16) 233 (6.33) 0.82 (0.67–0.99)
All-cause death 0.5
DM+/CKD+ 521 537 63 (15.58) 82 (20.66) 0.85 (0.61–1.18)
DM/CKD+ 1043 1117 80 (9.66) 125 (14.41) 0.70 (0.53–0.93)
DM+/CKD 1363 1385 64 (5.75) 69 (5.98) 0.98 (0.70–1.37)
DM/CKD 4621 4521 112 (2.87) 123 (3.21) 0.90 (0.69–1.16)
Stroke 0.6
DM+/CKD+ 521 537 13 (3.26) 18 (4.66) 0.78 (0.38–1.59)
DM/CKD+ 1043 1117 23 (2.81) 20 (2.33) 1.24 (0.68–2.26)
DM+/CKD 1363 1385 22 (1.99) 16 (1.40) 1.42 (0.75–2.71)
DM/CKD 4621 4521 40 (1.03) 31 (0.81) 1.28 (0.80–2.04)
Major bleeding 0.3
DM+/CKD+ 521 537 78 (27.37) 79 (26.89) 1.02 (0.75–1.40)
DM/CKD+ 1043 1117 129 (21.73) 125 (19.42) 1.13 (0.88–1.44)
DM+/CKD 1363 1385 150 (17.61) 171 (18.88) 0.91 (0.73–1.13)
DM/CKD 4621 4521 420 (13.23) 355 (11.19) 1.16 (1.01–1.34)
Non-CABG-related major bleeding 0.7
DM+/CKD+ 521 537 39 (12.87) 32 (10.18) 1.32 (0.82–2.10)
DM/CKD+ 1043 1117 75 (12.15) 62 (9.14) 1.34 (0.96–1.88)
DM+/CKD 1363 1385 48 (5.30) 50 (5.13) 1.03 (0.69–1.52)
DM/CKD 4621 4521 129 (3.88) 97 (2.93) 1.30 (1.00–1.69)
The model is adjusted for age, sex, body mass index, heart rate, prior myocardial infarction, hypertension, dyslipidemia, angina pectoris, smoking status, previous percutaneous coronary
intervention or CABG, type of acute coronary syndrome and randomized treatment. CABG indicates coronary artery bypass graft; CKD, chronic kidney disease; DM, diabetes mellitus; HR,
hazard ratio; MI, myocardial infarction.
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and CKD Deﬁned by the Creatinine-Cystatin C CKD-EPI Equation
DM/CKD Subgroup Ticagrelor Patients (N)
Clopidogrel
Patients (N)
Ticagrelor Event
Rate, N (%)
Clopidogrel Event
Rate, N (%) HR (95% CI)
P Value
Interaction
Cardiovascular death/MI/stroke 0.265
DM+/CKD+ 633 631 105 (22.66) 158 (36.57) 0.68 (0.53–0.88)
DM/CKD+ 344 390 49 (19.68) 74 (27.22) 0.77 (0.54–1.11)
DM+/CKD 2841 2886 267 (11.79) 313 (13.64) 0.87 (0.74–1.03)
DM/CKD 2877 2797 191 (8.31) 201 (8.99) 0.92 (0.76–1.13)
Cardiovascular death 0.257
DM+/CKD+ 633 631 57 (11.52) 98 (20.70) 0.63 (0.45–0.87)
DM/CKD+ 344 390 25 (9.42) 40 (13.63) 0.74 (0.45–1.23)
DM+/CKD 2841 2886 103 (4.34) 112 (4.62) 0.96 (0.73–1.25)
DM/CKD 2877 2797 57 (2.39) 64 (2.75) 0.87 (0.61–1.24)
MI 0.734
DM+/CKD+ 633 631 53 (11.28) 77 (17.53) 0.71 (0.50–1.00)
DM/CKD+ 344 390 29 (11.57) 40 (14.61) 0.84 (0.52–1.36)
DM+/CKD 2841 2886 165 (7.24) 192 (8.31) 0.87 (0.71–1.08)
DM/CKD 2877 2797 124 (5.36) 134 (5.97) 0.89 (0.70–1.14)
All-cause death 0.481
DM+/CKD+ 633 631 68 (13.75) 106 (22.39) 0.70 (0.51–0.95)
DM/CKD+ 344 390 28 (10.55) 44 (14.99) 0.74 (0.46–1.20)
DM+/CKD 2841 2886 113 (4.76) 125 (5.15) 0.94 (0.73–1.21)
DM/CKD 2877 2797 64 (2.68) 81 (3.48) 0.77 (0.56–1.07)
Stroke 0.293
DM+/CKD+ 633 631 15 (3.08) 12 (2.57) 1.33 (0.62–2.85)
DM/CKD+ 344 390 5 (1.90) 6 (2.06) 0.95 (0.29–3.12)
DM+/CKD 2841 2886 33 (1.40) 41 (1.70) 0.82 (0.52–1.30)
DM/CKD 2877 2797 29 (1.22) 17 (0.73) 1.67 (0.92–3.05)
Major bleeding 0.143
DM+/CKD+ 633 631 74 (20.61) 74 (20.51) 1.03 (0.75–1.42)
DM/CKD+ 344 390 43 (23.41) 43 (19.59) 1.12 (0.74–1.71)
DM+/CKD 2841 2886 307 (16.44) 322 (16.72) 0.97 (0.83–1.14)
DM/CKD 2877 2797 272 (14.15) 212 (10.97) 1.28 (1.07–1.54)
Non-CABG-related major bleeding 0.782
DM+/CKD+ 633 631 48 (12.89) 40 (10.69) 1.29 (0.84–1.96)
DM/CKD+ 344 390 23 (12.06) 21 (9.15) 1.36 (0.75–2.45)
DM+/CKD 2841 2886 93 (4.71) 87 (4.23) 1.12 (0.84–1.50)
DM/CKD 2877 2797 95 (4.71) 66 (3.29) 1.39 (1.02–1.91)
The model is adjusted for age, sex, BMI, heart rate, prior myocardial infarction, hypertension, dyslipidemia, angina pectoris, smoking status, previous PCI or CABG, type of ACS, and
randomized treatment. ACS indicates acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass graft; CKD, chronic kidney disease; CKD-EPI, chronic kidney disease
epidemiology collaboration; DM, diabetes mellitus; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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